This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through February 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
WGS, Zevra Partner to Launch Genetic Testing for Niemann-Pick Type C
by Zacks Equity Research
GeneDx launches Zevra-backed testing program to expand ExomeDx access for Niemann-Pick Type C, aiming to speed diagnosis and add data to its Infinity dataset.
ISRGPositive Net Change CAHNegative Net Change PAHCNegative Net Change WGSNegative Net Change
medical medical-devices
Reasons to Add West Pharmaceutical Stock to Your Portfolio Right Now
by Zacks Equity Research
WST eyes growth from high-value components, GLP-1 drug demand and Annex 1 conversions, but generics destocking and European capacity constraints pose risks.
ISRGPositive Net Change CAHNegative Net Change WSTPositive Net Change PAHCNegative Net Change
medical medical-devices
SNN Launches ALLEVYN COMPLETE CARE Dressing for Wound Management
by Zacks Equity Research
Smith + Nephew launches ALLEVYN COMPLETE CARE foam dressing for wound management, expanding its Advanced Wound Management portfolio.
SNNPositive Net Change ISRGPositive Net Change CAHNegative Net Change PAHCNegative Net Change
medical medical-devices
Reasons to Add AngioDynamics Stock to Your Portfolio for Now
by Zacks Equity Research
ANGO stock is buoyed by strong fiscal Q2 results, surging NanoKnife adoption in prostate cancer and broad Med Tech growth supporting margins.
ANGOPositive Net Change ISRGPositive Net Change CAHNegative Net Change PAHCNegative Net Change
medical medical-devices
Leonardo DRS, Inc. (DRS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
DRSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?
by Zacks Equity Research
ILMN stock surges 44.8% in a year, fueled by NovaSeq X sequencing demand, broader NGS testing adoption, multiomics expansion and improving margins.
ISRGPositive Net Change EWNegative Net Change ILMNNegative Net Change GMEDPositive Net Change
medical medical-devices
Intuitive Surgical Poised for Growth in 2026 on da Vinci 5 Momentum
by Indrajit Bandyopadhyay
ISRG rides da Vinci 5 momentum as procedure volumes surge, global adoption expands and Ion and SP platforms boost recurring revenue growth into 2026.
MDTNegative Net Change SYKNegative Net Change ISRGPositive Net Change
medical medical-devices
Stryker Introduces SmartHospital Platform to Advance Connected Care
by Zacks Equity Research
SYK unveils SmartHospital Platform to link devices, data and care teams, aiming to boost hospital efficiency, clinical decisions and digital transformation.
SYKNegative Net Change ISRGPositive Net Change PAHCNegative Net Change GEHCNegative Net Change
medical medical-devices
Hims and Hers Expands Consumer-Focused Digital Health Platform
by Debanjana Dey
HIMS expands its digital care platform with new specialties, lab testing and global moves as it scales personalized telehealth services.
MEDNegative Net Change HIMSPositive Net Change TEMPositive Net Change
medical medical-devices
GEHC Wins FDA 510(k) Approval for View, Enhances Radiology Workflows
by Zacks Equity Research
GE HealthCare wins FDA 510(k) clearance for View, a cloud-native imaging viewer in Genesis Radiology Workspace aimed at improving radiology workflows.
ISRGPositive Net Change CAHNegative Net Change PAHCNegative Net Change GEHCNegative Net Change
medical medical-devices